1102. Efficacy of antimicrobial Gendine gloves in a broad-spectrum rapid-kill assessment of multidrug-resistant organisms including CRE pathogens
Session: Poster Abstract Session: Infection Prevention: Hand Hygiene and PPE
Friday, October 9, 2015
Room: Poster Hall

Background: Contaminated gloves are a major source of transmission of emerging hospital associated infection (HAI) pathogens in hospitals. Previously we showed that Gendine gloves have significant antimicrobial efficacy and rapidly kill common HAI pathogens.  In this study we investigated the efficacy of Gendine gloves against a broad spectrum of multi-drug resistant (MDR) gram-positive organisms, carbapenem-resistant (CRE) and MDR gram-negative organisms, and yeast organisms that represent potential HAI pathogens.

Methods: Disposable nitrile gloves were coated with a proprietary biopolymer film containing Gendine . The efficacy of the Gendine-coated gloves was tested following the quantitative ISO 22196 method. Briefly, 8 cmthin films were cut from each glove and were exposed independently to 2.5x105 CFU of multiple multi-drug resistant and carbapenem-resistant clinical isolates obtained from our hospital. After 30 seconds and 1 minute after exposure, an excess of neutralizing broth was applied to halt all antiseptic activity. The broth was recovered and plated on agar. Viable colonies were enumerated following 24 hrs incubation at 37 C and results reported as CFU/film.

Results: Complete kill was obtained for all organisms within in 1 minute with the Gendine-nitrile films.  A significant (p<0.001), greater than 4-log10 reduction is achieved within 30 seconds (for organisms except C. albicans) and 1 minute for all organisms compared to control (see below). 

Conclusion: A novel disposable glove coated with Gendine was highly effective in rapidly eradicating a broad spectrum of emerging multi-drug nosocomial pathogens. The Gendine gloves warrants further study in a clinical setting for reduction of contract transmission of pathogens as an adjunct to current infection control measures.

 

Organism

Uncoated Control

Gendine (1minute)

MRSA

5.05x104

0

MRSE

9.5x104

0

VRE

8.4x104

0

MDR Pseudomonas aeruginosa

2.5x105

0

MDR E. coli

7.2x104

0

MDR Acinetobacter

1.21x104

0

MDR Stenotrophomonas

6.68x105

0

MDR Enterobacter

3.73x105

0

MDR Klebsiella pneumoniae

2.84x105

0

CRE E. coli

3.05x105

0

CRE Klebsiella pneumoniae

2.85x105

0

Serratia marcesens

6.28x105

0

Candida albicans

9.09x103

0

 

Ruth Reitzel, MS, Infectious Diseases, Infection Control & Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, Joel Rosenblatt, PhD, 1515 Holcombe - Suite FCT12.6030, UT MD Anderson Cancer Center, Houston, TX, Ray Hachem, MD, FIDSA, University of Texas, M.D. Anderson Cancer Center, Houston, TX and Issam Raad, MD, FACP, FIDSA, FSHEA, Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX

Disclosures:

R. Reitzel, None

J. Rosenblatt, UT MD Anderson Cancer Center: Shareholder , Licensing agreement or royalty
Novel Anti-Infective Technologies LLC: Shareholder , Licensing agreement or royalty

R. Hachem, None

I. Raad, UT MD Anderson Cancer Center: Shareholder , Licensing agreement or royalty
Novel Anti-Infective Technologies LLC: Shareholder , Licensing agreement or royalty

<< Previous Abstract | Next Abstract

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.